BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 15623659)

  • 1. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
    Zhao R; Chattopadhyay S; Hanscom M; Goldman ID
    Clin Cancer Res; 2004 Dec; 10(24):8735-42. PubMed ID: 15623659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells.
    Chattopadhyay S; Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Dec; 10(23):7986-93. PubMed ID: 15585634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
    Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
    Zhao R; Hanscom M; Chattopadhyay S; Goldman ID
    Cancer Res; 2004 May; 64(9):3313-9. PubMed ID: 15126375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
    Zhao R; Babani S; Gao F; Liu L; Goldman ID
    Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.
    Sierra EE; Goldman ID
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
    Zhao R; Gao F; Hanscom M; Goldman ID
    Clin Cancer Res; 2004 Jan; 10(2):718-27. PubMed ID: 14760095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
    Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
    Bodmer N; Walters DK; Fuchs B
    Pediatr Blood Cancer; 2008 Apr; 50(4):905-8. PubMed ID: 17534933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells.
    Kühnel JM; Chiao JH; Sirotnak FM
    J Cell Physiol; 2000 Sep; 184(3):364-72. PubMed ID: 10911368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
    Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
    Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
    McGuire JJ; Haile WH; Yeh CC
    Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
    Westerhof GR; Jansen G; van Emmerik N; Kathmann I; Rijksen G; Jackman AL; Schornagel JH
    Cancer Res; 1991 Oct; 51(20):5507-13. PubMed ID: 1655252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
    Wang Y; Zhao R; Chattopadhyay S; Goldman ID
    Cancer Res; 2002 Nov; 62(22):6434-7. PubMed ID: 12438230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular identity and characterization of a Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on the activity of pemetrexed.
    Zhao R; Goldman ID
    Cancer Metastasis Rev; 2007 Mar; 26(1):129-39. PubMed ID: 17340171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.